Skip to content

Endometrial tissue ablation: a clinical trial.

Endometrial tissue ablation: a clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22028
Enrollment
160
Registered
2005-07-29
Start date
2005-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysfunctional uterine bleeding

Interventions

Hydrothermablator (HTA) system versus ablation with novasure.

Sponsors

Channa Klein; J.Kleijn@mmc.nl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Refractory menorrhagia with no definable organic cause (dysfunctional uterine bleeding); 2. Ages over 25 years old; 3. Uterine sound measurement of 6.0 ¨C 12 cm (external os to internal fundus); 4. Failed, contraindicated or intolerance to conservative (medical) therapy; 5. Menstrual Diary: A minimum PBLAC score of > 150 for 1 month; 6. Intracavitary pathology, such as type 2 fibromas and small polyps (¡Ü 2cm), confirmed by hysteroscopy or Saline Infused Sonography (SIS).

Exclusion criteria

Exclusion criteria: 1. Presence of bacteremia, sepsis, or other active systemic infection; 2. Active or recurrent chronic pelvic inflammatory disease; 3. Patients with documented coagulopathies; 4. Symptomatic endometriosis; 5. Prior uterine surgery (except low segment cesarean section) which interrupts the integrity of the uterine wall e.g., transmural myomectomy or classical cesarean section; 6. Prior endometrial ablations; 7. Patients on medications that could thin the myometrial muscle, such as long-term steroid use; 8. Patients on anticoagulants; 9. Desire to have children or to preserve fertility; 10. Patients currently on hormonal birth control therapy or unwilling to use a non-hormonal birth control post-ablation; 11. Abnormal/Obstructed Cavity as confirmed by hysterscopy, Saline Infused Sonography (SIS) or HSG. Specifically: 11.1 Septate or bicornuate uterus or other congenital malformation of the uterine cavity.

Design outcomes

Primary

MeasureTime frame
Patients satisfaction: At each follow up visit/ telephone call patients satisfaction was noted. Patients can express their level satisfaction by using - completely satisfied, satisfied, doubtful satisfied or not satisfied. It¡¯s also noted if any kind of reintervention is performed, such as the use of oral contraceptives or surgery.

Secondary

MeasureTime frame
1. Quality of life: All patients are asked to complete quality of life questionnaires at baseline, at two days, six weeks, three months, six months and twelve months after surgery. We evaluate quality of life with the medical outcomes study SF 36, the Rotterdam symptom checklist and a structured clinical history questionnaire; 2. Amennorhoea: At each follow up visit/ telephone call duration of menstruation, dysmennorhoea and presence of clots are registered. Patients also complete a pictorial chart.

Contacts

Public ContactJ. Kleijn

Máxima Medisch Centrum, Locatie Veldhoven, P.O. Box 7777

J.Kleijn@mmc.nl+31 (0)040 8888000

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)